Story
Neurocrine Biosciences Stock Declines on Vykat XR Safety Concerns and INGREZZA Pricing Risks

Shares of Neurocrine Biosciences (NBIX) declined in pre-market trading, extending a recent corrective trend as investors weigh safety signals for a newly acquired drug and unresolved pricing risks for its primary revenue driver. The stock fell 3.1% to $156.85 in pre-open trading on Wednesday, according to Investing.com.
Safety Concerns Linger for Prader-Willi Drug
The selling pressure follows a joint statement from three organizations that raised safety concerns related to Vykat XR, a treatment for Prader-Willi syndrome. The groups highlighted post-marketing safety data that included seven patient deaths and more than 100 reports of serious adverse events since the drug's approval in March 2025. An FDA database separately lists four deaths associated with the medication.
The organizations noted that these reports do not establish a direct causal relationship between the drug and the adverse outcomes. Neurocrine acquired Vykat XR, which treats the chronic, insatiable hunger known as hyperphagia, through its $2.9 billion acquisition of Soleno Therapeutics earlier this year.
AdUnresolved Pricing Risks and Market Dynamics
Adding to investor uncertainty is the potential impact of Medicare's Inflation Reduction Act on Neurocrine's flagship product, INGREZZA. Management has acknowledged that the legislation could create pricing pressure between 2027 and 2029 but has not quantified the potential financial impact, leaving a key risk unresolved.
Wednesday's decline appears to be stock-specific rather than driven by broader market sentiment, suggesting investors are taking profits after a partial recovery from its 52-week low of $122.14. Despite recent price target increases from several analysts, the absence of a fresh positive catalyst has allowed these underlying concerns to weigh on the stock.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.